NCT06727630View on ClinicalTrials.gov

A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 14, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

October 30, 2025

Conditions
Melanoma
Interventions
DRUG

PRJ1-3024

PRJ1-3024 is provided as capsules and is administered orally once a day

Trial Locations (1)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Zhuhai Yufan Biotechnologies Co., Ltd

INDUSTRY